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ABSTRACT 
In a double-blind, prospective study, 40 patients diagnosed with DSM-IV generalized anxiety 
disorder and stabilized on alprazolam therapy were randomized to receive the same dose of either 
conventional or sustained-released alprazolam for two weeks, followed by the other formulation of 
alprazolam in an identical dose for a further two weeks. Conventional alprazolam was administered 
thrice daily while the sustained-release formulation was administered once-daily, in the morning. 
Thirty four patients completed the study. Recruitment into the study was associated with a significant 
decrease in all measures of illness severity; however, no efficacy differences between the two 
forms of alprazolam were observed. Adverse effects, specifically insomnia, were reported more 
with the sustained-release formulation. It is concluded that once-daily sustained-release alprazolam 
is as effective as the conventional form of the drug, and may be preferable because of a wide range 
of advantages; in this study, the higher incidence of adverse effects with the sustained-release drug 
was probably an artefact of the experimental design, which fostered a (nighttime) state of partial 
drug withdrawal. 
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Alprazolam is a triazolobenzodiazepine 
which is effective in the management of several 
disorders, chiefly generalized anxiety, panic and 
depression (Andrade,2000). A disadvantage of 
alprazolam is that its anxiolytic efficacy wears 
off faster than its blood levels drop. Therefore, 
thrice or even 4 times daily dosing may be 
necessitated, despite which interdose anxiety is 
some times a clinical problem (Schweizer et al., 
1993). Such repeated daytime dosing is 
associated with sedation, cognitive slowing, 
psychomotor slowing, and other adverse effects 
that accompany the dose peaks. Repeated 
daytime dosing is also inconvenient, can be 
embarrassing at the patient's places of work, and 
predisposes to poor compliance and the 
consequences thereof. Finally, repeated daytime 
dosing repeatedly reminds the patient about his 
illness There therefore appears to be a need 
for a sustained-release preparation of alprazolam. 
In previous research, conducted in 
patients with panic disorder, sustained-release 
alprazolam was found to be as effective as 
conventional alprazolam; the sustained-release 
formulation was also well-tolerated (Schweizer 
etal.,1993; Pecknoldetal.,1994; Figueira.1995). 
Additionally, the sustained-release formulation 
was observed to be associated with a more -, 
favourable withdrawal profile (Schweizer et al., 
1993), and with a smaller risk for relapse 
(Pecknold,1993). 
To the best of the authors' knowledge, 
India is the only country in which a sustained-
release preparation of alprazolam is 
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commercially available (since 1998) The 
present study therefore sought to assess the 
anxiolytic efficacy and the adverse effect profile 
of sustained-release alprazolam, in comparison 
with the conventional formulation of the drug. 
MATERIAL AND METHOD 
The sample comprised consecutive 
outpatients diagnosed with Generalized Anxiety 
Disorder (DSM-IV; American Psychiatric 
Association, 1994), recruited from a psychiatric 
hospital and from the psychiatry department of 
a general hospital in an urban setting in South 
India To be eligible for selection into the study, 
all patients had to have been receiving 
conventional alprazolam therapy for a minimum 
of 2 weeks, at a dose that was considered 
clinically appropriate by the treating psychiatrist. 
Only patients stabilized on their individual 
regimes at an alprazolam dose of either 0.75 or 
1.5 mg per day were considered for recruitment. 
Further selection criteria included an absence 
of alcohol and/or substance abuse, and an 
absence of significant medical and/or psychiatric 
comorbidity that might have influenced either 
diagnosis of anxiety or response to alprazolam. 
The research protocol was approved by the 
Ethics Committee in the institution of the first 
author, and all patients provided written informed 
consent for participation in the study. 
Recruited subjects were randomized to 
receive either conventional or sustained-release 
alprazolam, in the same dose as at intake, for 
two weeks. Subsequently, they received the 
other formulation of alprazolam, again in the 
same dose, for a further two weeks. No other 
psychotropic medication was permitted during 
the study. 
Conventional alprazolam was 
administered in capsule form, in the dose of 0.25 
or 0.5 mg (as applicable) thrice a day. Sustained-
release alprazolam was also administered in 
capsule form, once in the morning. Lactose 
placebo was administered as capsule in the 
afternoon and night during the sustained-release 
phase of therapy. All capsules were identical in 
appearance, and the number of capsules at each 
time of day, and during each phase of therapy, 
was the same. 
The sustained-release form of drug, as 
described by the manufacturers, releases about 
15% of its contents during the first hour, and 
about 7-8% per hour thereafter Release is 
substantially complete 10-14 hours after oral 
administration. The structure of release thus 
permits once daily dosing When the dose is 
administered in the morning, relatively uniform 
blood levels are maintained during the day, 
leveis drop at night, during sleep, when the 
experience of anxiety is rare. 
Patients were rated at baseline, after two 
weeks of one form of alprazolam, and after a 
further two weeks on the other form of 
alprazolam, using the Hamilton Rating Scale for 
Anxiety (Bech et al ,1986), and using a Global 
Rating Scale. The latter was assessed by the 
patient and by the rater separately, with 
assessment points anchored as follows, and with 
decimal ratings encouraged : 0=no symptoms, 
1=mild symptoms; 2=moderate symptoms; 
3=severe symptoms; 4=very severe symptoms. 
Adverse effects were assessed after each phase 
of alprazolam therapy using the Systematic 
Assessment for Treatment Emergent Effects 
(SAFTEE; Levineand Schooler, 1986) checklist 
Neither patients nor rater were aware of 
the initial or final treatment assignment. The 
study was therefore double-blind. 
Statistical methods : Means were compared 
between groups using the independent sample 
Student's t' test Means were compared within 
the same subjects across time using repeated 
measures multivariate analysis of variance 
(RMANOVA) with Pillai's trace as the statistical 
criterion. Means from non-normal distributions 
were compared within the same subjects across 
two time points using the Wilcoxon signed ranks 
test. Preference for a particular drug at endpoint, 
or experience of a particular adverse effect, was 
assessed using the Chi square test with the 
assumption of equal proportions. All hypotheses, 
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wherever applicable, were two-tailed. Alpha for 
significance was set at p<0.05. 
RESULTS 
The sample comprised 40 subjects aged 
18-55 years, with a mean (standard deviation) 
[M(SD)] age of 37.8 (8.81) years. There were 22 
males and 18 females The M(SD) age of the 
males was 37.8 (9.4) years, while that of the 
females was 37.8 (8.4) years. The difference was 
not statistically significant (t=0.01, d.f.=38, NS). 
The duration of illness in the sample 
ranged from 6 to 96 months, with a M(SD) of 
36.5 (18.1) months. The duration of prior 
alprazolam exposure ranged from 2 to 36 weeks, 
with a M(SD) of 11.6 (8.9) weeks. 
Thirty-two (80%) patients were receiving 
alprazolam 0.75 mg per day, while 8 (20%) were 
receiving alprazolam 1.5 mg/day. Eighteen 
(45%) patients had been randomized to receive 
conventional alprazolam first, while the 
remaining 22 (55%) had been randomized to 
receive sustained-release alprazolam first. 
Four patients dropped out of the study 
during the conventional alprazolam assessment 
phase, while 2 dropped out during the sustained-
release alprazolam phase. Data from the 
remaining 34 patients were available for final 
efficacy and adverse effect analyses. 
The anxiety and global ratings at different 
time points of assessment are presented in 
table-1. There was a significant reduction in 
Hamilton anxiety ratings after induction into the 
study (Pillai's trace=0 47, f=14.00, d.f.=2,32, 
p<0.001); ratings however did not differ 
significantly between conventional and 
sustained-release formulations. There was a 
significant reduction in patients' global ratings 
of illness severity after induction into the study 
(Pillai's trace=0.53,f=18.39,d.f.=2,32, p<0.001); 
again, ratings did not differ significantly between 
conventional and sustained-release formulations. 
Finally, there was a significant reduction in the 
rater's global ratings of illness severity after 
induction into the study (Pillai's trace=0.20, 
f=3.90, d.f.=2,32, p=0.03); once again, ratings 
TABLE 1 
M (SD) ANXIETY AND GLOBAL ILLNESS RATINGS AT 
BASELINE, AFTER CONVENTIONAL ALPRAZOLAM 
AND AFTER SUSTAINED-RELEASE ALPRAZOLAM 
Variable 
Hamilton 
anxiety 
score 
Global 
rating 
(by patient) 
Global 
rating 
(by rater) 
Baseline 
18.0 
(5.4) 
18 
(0.6) 
1.3 
(0.6) 
After 
conventional 
alprazolam 
14.4 
(5.7) 
1.2 
(0.6) 
1.2 
(0.4) 
After 
sustained-release 
alprazolam 
15.2 
(6.3) 
1.3 
(0.8) 
1.1 
(0.7) 
TABLE 2 
ADVERSE EFFECTS REPORTED BY PATIENTS 
(N=34) RECEIVING CONVENTIONAL AND 
SUSTAINED-RELEASE ALPRAZOLAM 
Adverse effect 
Headache 
Insomnia 
Sedation 
Anxiety 
Cognitive problems 
Weakness 
Somatic complaints 
Conventional 
alprazolam 
8 
2 
2 
8 
0 
0 
3 
Sustained-release 
alprazolam 
10 
16 
2 
12 
3 
2 
2 
did not differ significantly between conventional 
and sustained-release formulations. 
The M(SD) number of adverse effects 
reported by the patients was 0.7 (1.0) with 
conventional alprazolam, and 1.4 (1.0) with the 
sustained-release formulation, the difference 
was statistically significant (Wilcoxon signed 
rank test, z=2.73, p=0.006). A qualitative 
analysis of adverse effects is presented in 
table 2. Insomnia, commoner with sustained-
released alprazolam, was the only adverse effect 
to significantly differentiate the two formulations 
(X
2=10.89. d.f.=1, p<0.001). 
Twenty (50%) subjects preferred the 
convention formulation of alprazolam while 12 
(30%) preferred the sustained-release formulation. 
Two (5%) subjects offered no preference. 
Preference for conventional alprazolam did not 
differe significantly from that for the sustained-
release drug (X
2=2.00, d.f.=1, NS). 
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| DISCUSSION 
This study found that anxious patients 
stabilized on alprazolam therapy experienced 
further improvement when recruited for research, 
although no dose changes had been effected, 
nor additional psychological or biological 
interventions instituted. It is likely that nonspecific 
factors or a placebo effect were responsible for 
the improvement; such responses are well known 
in both anxiety (Londborg et al.,1998; Andrade 
et al.,2000) and depressive (Weiss et al.1997) 
disorders. 
There was no significant difference 
obtained in efficacy ratings (on any measure) 
between conventional (thrice daily) and 
sustained-release (once-daily) formulations of 
alprazolam. This suggests that the sustained-
release drug is as effective as the conventional 
formulation, and can conveniently substitute for 
it in clinical practice because of the variety of 
advantages that it purveys. These advantages 
include a smoother onset of action, a more 
sustained effect due to the maintenance of 
uniform blood levels, less adverse effects (such 
as sedation, cognitive slowing and psychomotor 
slowing) associated with dosage peaks, less 
inconvenience/embarrassment at the workplace 
and better compliance due to once-daily 
administration, and lesser emphasis of illness 
due to once-daily administration (Andrade, 1999). 
Regrettably, the psychosocial advantages of 
once-daily dosing could not be empirically 
studied in the present investigation because of 
the need for double-blindness, which 
necessitated afternoon and nighttime dosing 
(with placebo) even during the sustained-release 
phase of therapy. 
Previous research, conducted in patients 
with panic disorder, showed that once-daily 
sustained-release alprazolam was as effective 
and as well-tolerated as thrice-daily conventional 
alprazolam (Schweizer et al.,1993; Pecknold et 
al.,1994). One study, conducted on patients with 
generalized anxiety disorder, found that once-daily 
sustained-release alprazolam was as affective 
and as well-tolerated as thrice-daily bromazepam 
(Figueira,1995). To the best of our knowledge, 
this is the first study to compare the two 
formulations of alprazolam in a crossover design. 
In this study, treatment with sustained-
release alprazolam was associated with 
significantly more adverse effects. Only 
insomnia was present significantly more 
commonly with the sustained-release form. This 
was probably an artefact of the research design. 
Patients had been stabilized on thrice-daily 
conventional alprazolam therapy prior to intake; 
thus, all had been receiving nighttime 
alprazolam, and had been conditioned to a 
nighttime peak in the blood level of the drug. 
During the sustained-release phase, alprazolam 
therapy was limited to a single morning dose. 
The pharmacokinetics of the formulation resulted 
in terminal absorption by evening; this would 
necessarily be followed by a drop in blood levels 
at night. As a consequence, the patient would 
experience a state of relative drug withdrawal at 
night, in contrast with his prior experience of a 
peak in blood levels with the nighttime dose of 
conventional alprazolam. The result would be 
insomnia with the sustained-release drug. 
This experience suggests that alprazolam 
therapy should ideally be directly initiated with the 
sustained-release formulation in order to prevent 
prior habituation to a night time peak in blood levels 
of the drug; or, in patients already on conventional 
alprazolam, and in those already experiencing 
insomnia, twice-daily dosing with the sustained-
release formulation may be considered. A 
nighttime dose of the sustained-release formulation 
may also be considered in patients who report 
anxiety or panic during the night or early morning, 
at which time alprazolam levels are low. 
Interestingly, no patient reported early 
morning anxiety during the sustained-release 
alprazolam phase, indicating that the decrease 
in drug levels during the night and early morning 
is not associated with breathrough anxiety. This 
finding underlines the acceptability of once-daily 
dosing, which is a major advantage with the 
sustained-release formulation. This finding also 
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draws attention to the need to study psycho-
biological phenomena which are associated with 
diurnal variations in anxiogenesis. 
Greater sedation with conventional 
alprazolam was expected but not observed in 
this study. One explanation is that the doses used 
in this study were relatively low compared to 
those common in panic disorder. Another 
explanation is that patients were stabilized on 
conventional alprazolam therapy before intake; 
this meant that their doses would have been 
adjusted for maximum efficacy and minimum 
adverse effects, and that tolerance to the 
sedative adverse effects would already have 
developed. 
Although numerically more subjects 
favoured the use of the conventional formulation, 
this finding did not attain statistical significance, 
perhaps because of a type 2 error arising from 
the small sample size. The numerical preference 
for the conventional formulation may have due 
to the relative withdrawal' type of adverse 
effects referred to earlier. 
In conclusion, once-daily sustained-
release alprazolam was as effective as thrice-
daily conventional alprazolam; the greater 
experience of adverse effects (particularly 
insomnia) with the sustained-release formulation 
was probably an artefact of the experimental 
design, which fostered a state of relative drug 
withdrawal at night during the sustained-release 
drug phase. Sustained-release alprazolam, 
administered once or twice daily, may be a useful 
therapeutic strategy for the management of 
anxiety disorders, in view of the pharmacokinetic 
and psychosocial advantages that it carries. 
Future research could be directed to the 
study of drug-naive patients, to demonstrate the 
possible better tolerability and acceptance of 
sustained-release alprazolam. Naturalistic 
studies could examine issues such as long-term 
efficacy, compliance and withdrawal. Of 
particular interest in the context of 
discontinuation of sustained-release alprazolam 
therapy is the possibility of lowered risk for 
withdrawal symptoms, rebound, and relapse in 
patients with generalized anxiety disorder, as has 
been reported in patients with panic disorder 
(Schweizer et al.,1993; Pecknold,1994). 
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